Osteoarthritis Pain - Pipeline Review, H2 2016

Date: October 29, 2016
Pages: 212
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: O0482EE8AA0EN
Leaflet:

Download PDF Leaflet

Osteoarthritis Pain - Pipeline Review, H2 2016
Osteoarthritis Pain - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoarthritis Pain - Pipeline Review, H2 2016, provides an overview of the Osteoarthritis Pain (Central Nervous System) pipeline landscape.

Osteoarthritis pain is the most common symptom associated with osteoarthritis which causes disruption of the cartilage. This further leads to rubbing of the bones against each other stimulating pain. The predisposing factors are age, joint injury, obesity and heredity. It may be diagnosed by physical examination and MRI and X-ray imaging. The condition may be controlled by weight control, exercise and medication.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteoarthritis Pain - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Osteoarthritis Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteoarthritis Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Osteoarthritis Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 7, 19, 6, 1, 17, 5 and 1 respectively for Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively for Osteoarthritis Pain.

Osteoarthritis Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoarthritis Pain (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Osteoarthritis Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Osteoarthritis Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Osteoarthritis Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Osteoarthritis Pain (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Osteoarthritis Pain (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Osteoarthritis Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Osteoarthritis Pain Overview
Therapeutics Development
Osteoarthritis Pain - Therapeutics under Development by Companies
Osteoarthritis Pain - Therapeutics under Investigation by Universities/Institutes
Osteoarthritis Pain - Pipeline Products Glance
Osteoarthritis Pain - Products under Development by Companies
Osteoarthritis Pain - Products under Investigation by Universities/Institutes
Osteoarthritis Pain - Companies Involved in Therapeutics Development
Osteoarthritis Pain - Therapeutics Assessment
Drug Profiles
Osteoarthritis Pain - Dormant Projects
Osteoarthritis Pain - Discontinued Products
Osteoarthritis Pain - Product Development Milestones
Appendix 204

LIST OF TABLES

Number of Products under Development for Osteoarthritis Pain, H2 2016
Number of Products under Development for Osteoarthritis Pain - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Investigation by Universities/Institutes, H2 2016
Osteoarthritis Pain - Pipeline by AbbVie Inc, H2 2016
Osteoarthritis Pain - Pipeline by Addex Therapeutics Ltd, H2 2016
Osteoarthritis Pain - Pipeline by Afferent Pharmaceuticals, Inc., H2 2016
Osteoarthritis Pain - Pipeline by Akron Molecules AG, H2 2016
Osteoarthritis Pain - Pipeline by Allergan Plc, H2 2016
Osteoarthritis Pain - Pipeline by Ampio Pharmaceuticals, Inc., H2 2016
Osteoarthritis Pain - Pipeline by Antibe Therapeutics, Inc., H2 2016
Osteoarthritis Pain - Pipeline by Aralez Pharmaceuticals Inc., H2 2016
Osteoarthritis Pain - Pipeline by Arena Pharmaceuticals, Inc., H2 2016
Osteoarthritis Pain - Pipeline by Array BioPharma Inc., H2 2016
Osteoarthritis Pain - Pipeline by AskAt Inc., H2 2016
Osteoarthritis Pain - Pipeline by Astellas Pharma Inc., H2 2016
Osteoarthritis Pain - Pipeline by Axsome Therapeutics Inc, H2 2016
Osteoarthritis Pain - Pipeline by Biogen Inc, H2 2016
Osteoarthritis Pain - Pipeline by Boehringer Ingelheim GmbH, H2 2016
Osteoarthritis Pain - Pipeline by Cara Therapeutics, Inc., H2 2016
Osteoarthritis Pain - Pipeline by Centrexion Therapeutics Corp, H2 2016
Osteoarthritis Pain - Pipeline by Chromocell Corporation, H2 2016
Osteoarthritis Pain - Pipeline by Eli Lilly and Company, H2 2016
Osteoarthritis Pain - Pipeline by Elite Pharmaceuticals, Inc., H2 2016
Osteoarthritis Pain - Pipeline by Eupraxia Pharmaceuticals Inc., H2 2016
Osteoarthritis Pain - Pipeline by Flexion Therapeutics, Inc., H2 2016
Osteoarthritis Pain - Pipeline by Genzyme Corporation, H2 2016
Osteoarthritis Pain - Pipeline by GlaxoSmithKline Plc, H2 2016
Osteoarthritis Pain - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016
Osteoarthritis Pain - Pipeline by Grunenthal GmbH, H2 2016
Osteoarthritis Pain - Pipeline by Iroko Pharmaceuticals, LLC, H2 2016
Osteoarthritis Pain - Pipeline by Medestea Research & Production S.p.A., H2 2016
Osteoarthritis Pain - Pipeline by MedImmune, LLC, H2 2016
Osteoarthritis Pain - Pipeline by Nuvo Pharmaceuticals Inc., H2 2016
Osteoarthritis Pain - Pipeline by Pfizer Inc., H2 2016
Osteoarthritis Pain - Pipeline by Phosphagenics Limited, H2 2016
Osteoarthritis Pain - Pipeline by pSivida Corp., H2 2016
Osteoarthritis Pain - Pipeline by Purdue Pharma LP, H2 2016
Osteoarthritis Pain - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016
Osteoarthritis Pain - Pipeline by Symic Biomedical, Inc., H2 2016
Osteoarthritis Pain - Pipeline by Taiwan Liposome Company, Ltd., H2 2016
Osteoarthritis Pain - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2016
Osteoarthritis Pain - Pipeline by Zynerba Pharmaceuticals Inc, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Osteoarthritis Pain - Dormant Projects, H2 2016
Osteoarthritis Pain - Dormant Projects (Contd..1), H2 2016
Osteoarthritis Pain - Dormant Projects (Contd..2), H2 2016
Osteoarthritis Pain - Dormant Projects (Contd..3), H2 2016
Osteoarthritis Pain - Dormant Projects (Contd..4), H2 2016
Osteoarthritis Pain - Discontinued Products, H2 2016
Osteoarthritis Pain - Discontinued Products (Contd..1), H2 2016 200

LIST OF FIGURES

Number of Products under Development for Osteoarthritis Pain, H2 2016
Number of Products under Development for Osteoarthritis Pain - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Inflammatory Pain - Pipeline Review, H2 2014 US$ 1,500.00 Jul, 2014 · 164 pages
Visceral Pain - Pipeline Review, H2 2016 US$ 2,000.00 Aug, 2016 · 58 pages
Visceral Pain - Pipeline Review, H1 2016 US$ 1,700.00 Mar, 2016 · 64 pages
Ocular Pain - Pipeline Review, H2 2016 US$ 2,000.00 Aug, 2016 · 70 pages

Ask Your Question

Osteoarthritis Pain - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: